Cambien François
INSERM U525, Chu Pitié-Salpétrière Université Pierre et Marie Curie, 91 Bd de l'Hôpital, 75013 Paris, France.
Curr Atheroscler Rep. 2005 May;7(3):188-95. doi: 10.1007/s11883-005-0005-5.
Several biologic systems contribute to the pathophysiology of atherosclerosis and its complications, and within each of these systems many genes have been explored to establish the possible implication of their variability in coronary heart disease (CHD) risk. This report is focused on recent results pertaining to lipid and inflammatory genes, their variability, and their relationship with intermediate phenotypes and CHD. For both systems, there is no evidence at the present time that testing genetic polymorphisms might be of any benefit to the patient, for the diagnosis or prognosis of CHD, or for tailoring drug prescription. Understanding the genetics of complex traits like CHD will require a system approach that allows a modeling of the interaction among genes as well as between genetic and nongenetic sources of variation.
多种生物系统参与动脉粥样硬化及其并发症的病理生理过程,在这些系统中的每一个系统内,人们都对许多基因进行了探索,以确定其变异性在冠心病(CHD)风险中的可能影响。本报告重点关注与脂质和炎症基因、它们的变异性以及它们与中间表型和冠心病之间关系的最新研究结果。对于这两个系统,目前没有证据表明检测基因多态性对患者在冠心病的诊断、预后或药物处方调整方面有任何益处。理解像冠心病这样复杂性状的遗传学需要一种系统方法,该方法能够对基因之间以及遗传和非遗传变异来源之间的相互作用进行建模。